WO2007142202A1 - ヌクレオチド鎖修飾方法 - Google Patents
ヌクレオチド鎖修飾方法 Download PDFInfo
- Publication number
- WO2007142202A1 WO2007142202A1 PCT/JP2007/061309 JP2007061309W WO2007142202A1 WO 2007142202 A1 WO2007142202 A1 WO 2007142202A1 JP 2007061309 W JP2007061309 W JP 2007061309W WO 2007142202 A1 WO2007142202 A1 WO 2007142202A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleotide
- nucleotide chain
- modifying
- substance
- enzyme
- Prior art date
Links
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 290
- 239000002773 nucleotide Substances 0.000 title claims abstract description 285
- 238000000034 method Methods 0.000 title claims abstract description 76
- 238000006243 chemical reaction Methods 0.000 claims abstract description 64
- 102000004190 Enzymes Human genes 0.000 claims abstract description 38
- 108090000790 Enzymes Proteins 0.000 claims abstract description 38
- 125000000524 functional group Chemical group 0.000 claims abstract description 21
- 239000000126 substance Substances 0.000 claims description 104
- 239000002585 base Substances 0.000 claims description 35
- 239000000758 substrate Substances 0.000 claims description 34
- 239000000872 buffer Substances 0.000 claims description 33
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 claims description 30
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 30
- 125000003172 aldehyde group Chemical group 0.000 claims description 21
- 125000003277 amino group Chemical group 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 239000011541 reaction mixture Substances 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- 238000007259 addition reaction Methods 0.000 claims description 13
- 229910001429 cobalt ion Inorganic materials 0.000 claims description 13
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims description 13
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 12
- 108020001738 DNA Glycosylase Proteins 0.000 claims description 10
- 102000028381 DNA glycosylase Human genes 0.000 claims description 10
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 10
- 238000006011 modification reaction Methods 0.000 claims description 9
- 239000001226 triphosphate Substances 0.000 claims description 9
- 229930024421 Adenine Natural products 0.000 claims description 8
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 claims description 8
- 239000012190 activator Substances 0.000 claims description 8
- 229960000643 adenine Drugs 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 235000011178 triphosphate Nutrition 0.000 claims description 8
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 8
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 7
- 230000000593 degrading effect Effects 0.000 claims description 7
- 229910001437 manganese ion Inorganic materials 0.000 claims description 7
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 7
- 102000011724 DNA Repair Enzymes Human genes 0.000 claims description 6
- 108010076525 DNA Repair Enzymes Proteins 0.000 claims description 6
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 6
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 claims description 6
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 229940104302 cytosine Drugs 0.000 claims description 6
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 6
- 150000004712 monophosphates Chemical class 0.000 claims description 6
- 229940113082 thymine Drugs 0.000 claims description 6
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 claims description 5
- 150000001768 cations Chemical class 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical group [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims description 4
- 125000005370 alkoxysilyl group Chemical group 0.000 claims description 4
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- 102000015636 Oligopeptides Human genes 0.000 claims description 3
- 108010038807 Oligopeptides Proteins 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 125000005372 silanol group Chemical group 0.000 claims description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 claims 1
- 239000003607 modifier Substances 0.000 abstract description 15
- 239000007853 buffer solution Substances 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 7
- 239000007788 liquid Substances 0.000 abstract description 3
- 230000035484 reaction time Effects 0.000 abstract 1
- 238000002372 labelling Methods 0.000 description 26
- 238000002715 modification method Methods 0.000 description 16
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 230000010076 replication Effects 0.000 description 13
- 102100037111 Uracil-DNA glycosylase Human genes 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 10
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- -1 2-morpholino ethane sulfone Chemical class 0.000 description 7
- 238000000354 decomposition reaction Methods 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 229940035893 uracil Drugs 0.000 description 7
- KAXHGGVDHLXVMS-BHQGJQQGSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-aminooxypentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(ON)C(O)=O)SC[C@@H]21 KAXHGGVDHLXVMS-BHQGJQQGSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000005547 deoxyribonucleotide Substances 0.000 description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 6
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 5
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910000510 noble metal Inorganic materials 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 5
- FSASIHFSFGAIJM-UHFFFAOYSA-N 3-methyladenine Chemical compound CN1C=NC(N)=C2N=CN=C12 FSASIHFSFGAIJM-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229910017052 cobalt Inorganic materials 0.000 description 4
- 239000010941 cobalt Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 229910052748 manganese Inorganic materials 0.000 description 4
- 239000011572 manganese Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 229910000077 silane Inorganic materials 0.000 description 4
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 239000002262 Schiff base Substances 0.000 description 3
- 150000004753 Schiff bases Chemical class 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- 108010034927 3-methyladenine-DNA glycosylase Proteins 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- OLXZPDWKRNYJJZ-UHFFFAOYSA-N 5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(CO)O1 OLXZPDWKRNYJJZ-UHFFFAOYSA-N 0.000 description 2
- OFJNVANOCZHTMW-UHFFFAOYSA-N 5-hydroxyuracil Chemical compound OC1=CNC(=O)NC1=O OFJNVANOCZHTMW-UHFFFAOYSA-N 0.000 description 2
- RGKBRPAAQSHTED-UHFFFAOYSA-N 8-oxoadenine Chemical compound NC1=NC=NC2=C1NC(=O)N2 RGKBRPAAQSHTED-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- KZCOBXFFBQJQHH-UHFFFAOYSA-N octane-1-thiol Chemical compound CCCCCCCCS KZCOBXFFBQJQHH-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- ZDHURYWHEBEGHO-UHFFFAOYSA-N potassiopotassium Chemical compound [K].[K] ZDHURYWHEBEGHO-UHFFFAOYSA-N 0.000 description 2
- 239000010970 precious metal Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- GUKSGXOLJNWRLZ-UHFFFAOYSA-N thymine glycol Chemical compound CC1(O)C(O)NC(=O)NC1=O GUKSGXOLJNWRLZ-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- ILROLYQPRYHHFG-UHFFFAOYSA-N 1-$l^{1}-oxidanylprop-2-en-1-one Chemical group [O]C(=O)C=C ILROLYQPRYHHFG-UHFFFAOYSA-N 0.000 description 1
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2'-deoxyguanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- XHBSBNYEHDQRCP-UHFFFAOYSA-N 2-amino-3-methyl-3,7-dihydro-6H-purin-6-one Chemical compound O=C1NC(=N)N(C)C2=C1N=CN2 XHBSBNYEHDQRCP-UHFFFAOYSA-N 0.000 description 1
- SULBUWBTSDCEDY-UHFFFAOYSA-N 2-amino-7-(2-chloroethyl)-3h-purin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N=CN2CCCl SULBUWBTSDCEDY-UHFFFAOYSA-N 0.000 description 1
- ISSUJOQDZTTZOM-UHFFFAOYSA-N 2-amino-7-(2-ethoxyethyl)-3h-purin-6-one Chemical compound N1=C(N)NC(=O)C2=C1N=CN2CCOCC ISSUJOQDZTTZOM-UHFFFAOYSA-N 0.000 description 1
- OCAWYYAMQRJCOY-UHFFFAOYSA-N 2-amino-7-(2-hydroxyethyl)-3h-purin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N=CN2CCO OCAWYYAMQRJCOY-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- ZSWIFYLVIOANLQ-UHFFFAOYSA-N 3-(2-ethylsulfanylethyl)purine Chemical compound CCSCCN1C=NC=C2N=CN=C12 ZSWIFYLVIOANLQ-UHFFFAOYSA-N 0.000 description 1
- XAZTXNQITCBSCJ-UHFFFAOYSA-N 3-ethyl-7H-purin-6-imine Chemical compound CCn1cnc(=N)c2[nH]cnc12 XAZTXNQITCBSCJ-UHFFFAOYSA-N 0.000 description 1
- KLNMBAPDSXHFFB-UHFFFAOYSA-N 3-ethylpurine Chemical compound CCN1C=NC=C2N=CN=C12 KLNMBAPDSXHFFB-UHFFFAOYSA-N 0.000 description 1
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 description 1
- KUWKZPPHDXGFDF-UHFFFAOYSA-N 4-[2-aminoethyl(dimethoxy)silyl]butan-1-amine Chemical compound NCC[Si](OC)(OC)CCCCN KUWKZPPHDXGFDF-UHFFFAOYSA-N 0.000 description 1
- NHOKUDODDWSIAJ-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazinane-2,4-dione Chemical compound OC1NC(=O)NC(=O)C1O NHOKUDODDWSIAJ-UHFFFAOYSA-N 0.000 description 1
- YFQOVSGFCVQZSW-UHFFFAOYSA-N 5,6-dihydroxyuracil Chemical compound OC=1NC(=O)NC(=O)C=1O YFQOVSGFCVQZSW-UHFFFAOYSA-N 0.000 description 1
- OHAMXGZMZZWRCA-UHFFFAOYSA-N 5-formyluracil Chemical compound OC1=NC=C(C=O)C(O)=N1 OHAMXGZMZZWRCA-UHFFFAOYSA-N 0.000 description 1
- UIHWKXHRHOBLKQ-UHFFFAOYSA-N 5-hydroxy-5-methyl-1,3-diazinane-2,4-dione Chemical compound CC1(O)CNC(=O)NC1=O UIHWKXHRHOBLKQ-UHFFFAOYSA-N 0.000 description 1
- NTUVVWKLOXHUNZ-UHFFFAOYSA-N 8,9-dihydro-7H-imidazo[2,1-f]purine Chemical compound C1=NC2=NC=NC2=C2NCCN21 NTUVVWKLOXHUNZ-UHFFFAOYSA-N 0.000 description 1
- BWUPKMHSAHUZGN-UHFFFAOYSA-N 8-aminooctane-1-thiol Chemical compound NCCCCCCCCS BWUPKMHSAHUZGN-UHFFFAOYSA-N 0.000 description 1
- UBKVUFQGVWHZIR-UHFFFAOYSA-N 8-oxoguanine Chemical compound O=C1NC(N)=NC2=NC(=O)N=C21 UBKVUFQGVWHZIR-UHFFFAOYSA-N 0.000 description 1
- CFRFHWQYWJMEJN-UHFFFAOYSA-N 9h-fluoren-2-amine Chemical compound C1=CC=C2C3=CC=C(N)C=C3CC2=C1 CFRFHWQYWJMEJN-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 108010046855 DNA-deoxyinosine glycosidase Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 102100032975 Myosin-1 Human genes 0.000 description 1
- 101710204036 Myosin-1 Proteins 0.000 description 1
- OSXKHFTZRHDUJN-UHFFFAOYSA-N N(2),3-ethenoguanine Chemical compound O=C1NC2=NC=CN2C2=C1NC=N2 OSXKHFTZRHDUJN-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101710086015 RNA ligase Proteins 0.000 description 1
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001495 arsenic compounds Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 125000005340 bisphosphate group Chemical group 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- KOGINMITGZVQBD-UHFFFAOYSA-N ethanesulfonic acid;piperazine Chemical compound CCS(O)(=O)=O.C1CNCCN1 KOGINMITGZVQBD-UHFFFAOYSA-N 0.000 description 1
- VHPSTQHBAKJOKG-UHFFFAOYSA-N formamide;7h-purin-6-amine Chemical compound NC=O.NC1=NC=NC2=C1NC=N2 VHPSTQHBAKJOKG-UHFFFAOYSA-N 0.000 description 1
- HDLHSPLHIYZZER-UHFFFAOYSA-N formamide;pyrimidine Chemical compound NC=O.C1=CN=CN=C1 HDLHSPLHIYZZER-UHFFFAOYSA-N 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- YLZGECKKLOSBPL-UHFFFAOYSA-N indium nickel Chemical compound [Ni].[In] YLZGECKKLOSBPL-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000003380 quartz crystal microbalance Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002683 reaction inhibitor Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- YHULXGUCQZFROV-UHFFFAOYSA-N sulfane;urea Chemical compound S.NC(N)=O YHULXGUCQZFROV-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- NBXZNTLFQLUFES-UHFFFAOYSA-N triethoxy(propyl)silane Chemical compound CCC[Si](OCC)(OCC)OCC NBXZNTLFQLUFES-UHFFFAOYSA-N 0.000 description 1
- YUYCVXFAYWRXLS-UHFFFAOYSA-N trimethoxysilane Chemical compound CO[SiH](OC)OC YUYCVXFAYWRXLS-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
Definitions
- the present invention relates to a method for modifying a nucleotide chain, and more particularly to a method for labeling, labeling, and immobilizing a nucleotide chain by directly modifying the terminal end of the nucleotide chain with a modifying substance.
- radioactive isotopes have been adopted as modifiers for labeling and labeling nucleotide chains such as DNA, RNA, oligonucleotides, and nucleic acids. Due to the limitation of the handling period due to the half-life, the restriction of the place of handling, the problem of exposure, the problem of disposal, etc., its use is decreasing. In recent years, fluorescent substances such as fluorescein or piotin have come to be widely used as modifiers to replace radioisotopes.
- alkaline phosphatase has the property of inducing dephosphorylation of the ⁇ -terminal of the nucleotide chain, it is often used as a modified substance. Nucleotide chain forces will be dissociated, and alkaline phosphatase cannot be used for nucleotide chains modified at the 5 'end.
- a nucleotide chain modified with a modifying substance is obtained by incorporating a nucleotide modified in advance using a nucleotide chain replication reaction or transcription reaction.
- a method has also been proposed.
- labeling with a radioisotope by conventional force, nick translation method, random primer method, primer extension method, etc., which are adopted in labeling, are exemplified.
- Deoxyribonucleotides that have been modified with a modifying substance in advance ⁇ Triphosphate is incorporated using the replication reaction of DNA polymerase, and in the transcription reaction, ribonucleotides that have been modified with a modifying substance in advance Triphosphate is incorporated using the transcription reaction of RNA polymerase (for example, Patent Documents 5 to 8 and Non-Patent Documents 6 and 8 to 9).
- These modification methods are suitable for gene analysis because they have the advantages of easy operation, high modification amount of the nucleotide chain, stability of the modification substance, and that the modification substance is not dissociated by alkaline phosphatase. It is widely used as a method.
- modification methods can be used in combination with the polymerase chain reaction, so-called PCR method or RNA amplification reaction, to simultaneously realize a gene amplification reaction, labeling, and labeling reaction (for example, Non-Patent Documents 10 to 12). ), And comprehensive analysis of genes generically called DNA microarrays (for example, Patent Documents 9 to 10 and Non-Patent Documents 13 to 15).
- the modification method by replication reaction or transcription reaction described above is a method of incorporating a nucleotide that has been modified with a modifying substance in advance, that is, a pseudo nucleotide, so that the incorporation efficiency is lower than that of the original nucleotide.
- a modifying substance for example, Patent Document 8 and Non-Patent Document 16
- the amount of modified substance incorporation is random at 12-25 molecules per nucleotide chain molecule.
- Yes for example, Non-Patent Document 17
- a nucleotide chain that is in the form of a saddle is required as in the modification method using the above-described replication reaction or transcription reaction.
- There is also a method of modifying For example, at the end of the nucleotide chain, there is a deoxyribonucleotide ⁇ triphosphate that has been previously modified with a modifier using terminal deoxynucleotidyl transferase, or a dideoxyribonucleotide ⁇ triphosphate.
- an acid tailing method for example, non-patent documents 19 to 21
- RNA ligase for example, RNA ligase.
- tailing bisphosphate for example, Patent Document 11 and Non-Patent Document 22.
- the method of tailing dideoxyribonucleotide 5'-triphosphate or the method of tailing ribonucleotide-3 5'-bisphosphate is a modifier for one molecule of the nucleotide chain.
- the method of tailing deoxyribonucleotide ⁇ triphosphate that has been modified in advance with a modifying substance can be modified with a multimolecular modifying substance for one molecule of the nucleotide chain.
- nucleotides modified with a modifying substance in advance are not easily synthesized by anyone, and as a result, the types of modifying substances are limited.
- the modification of the nucleotide chain is performed not only for labeling and labeling but also for immobilizing the nucleotide chain on the substrate.
- hydrophobic substrates have been used as fixed substrates.
- substrates such as nitrocellulose, nylon, and polyvinylidene fluoride that have been processed to have a positive charge are used, and the hydrophobic bond between the nucleotide chain and the substrate, and the phosphate group of the nucleotide chain (negative The nucleotide chain was immobilized on the substrate by electrostatic coupling between the substrate and the positively charged substrate.
- the nucleotide chain can be immobilized more stably and firmly than the conventional hydrophobic bond and electrostatic bond.
- the functional group and the linking group amino group-carboxyl group, amino group-isothiocyanate group, amino group-aldehyde group, amino group-succinimide group, amino group-epoxy group, etc. are used.
- the ⁇ -terminus of the nucleotide chain is modified with a modifying substance having a functional group, it is via a phosphate group, and the nucleotide chain is dissociated by the above problem, that is, phosphatase. Therefore, there arises a problem that detection by a luminescent reaction is difficult. Even when the ⁇ -terminus of the nucleotide chain is modified with a modifying substance having a functional group, the length of the nucleotide chain is limited in order to obtain the above-mentioned problem, that is, chemical synthesis and sufficient yield. The problem occurs.
- a tailing method in which a nucleotide previously modified with a modifying substance is added forms an unnecessary nucleotide sequence.
- Patent Document 10 can directly modify the nucleotide side of the nucleotide chain, which is related to the length of the nucleotide chain, with an arbitrary modifying substance.
- an addition reaction, a decomposition reaction, and a modification reaction are possible. In each case, it was necessary to recover the sample by changing the reaction conditions and ethanol precipitation, and it took more than 10 hours to complete the modification reaction.
- the present invention solves the above problems, and aims to minimize the change in reaction conditions and shorten the time required for directly modifying the ⁇ -terminus of a nucleotide chain with a modifying substance. To do.
- the nucleotide modification method of the present invention includes a nucleotide chain to be modified and a nucleotide having a specific base different from the base constituting the nucleotide chain in a buffer.
- an enzyme that catalyzes the addition of the nucleotide to the ⁇ -terminus of the nucleotide chain a degradation enzyme that specifically acts on the nucleotide, and a desired modifying substance that modifies the nucleotide chain coexist.
- the nucleotide is added to the ⁇ terminus of the nucleotide chain, and the sequence of the added nucleotide is decomposed to form a functional group having binding ability to the modifying substance at the ⁇ terminus of the nucleotide chain.
- the end of the nucleotide chain on which the functional group is formed is directly modified with the modifying substance.
- a series of reactions are performed without separating the reaction products in the mixed solution in the middle, and the nucleotide chain is directly modified with a modifying substance. This simplifies the operation and shortens the time. Convenient because it is not related to chain length.
- the nucleotide chain to be modified, the nucleotide, the modifying substance, and both enzymes may be mixed first to cause an addition reaction, a decomposition reaction, and a modification reaction in parallel;
- the addition chain and nucleotide and both enzymes may be mixed to cause an addition reaction and a decomposition reaction in parallel, and a modifying substance may be added to the mixed solution after the decomposition reaction to cause a modification reaction.
- an activator that activates an enzyme that catalyzes an addition reaction an activator that does not inhibit the modification reaction of the modifying substance is added. This is because it is desirable that the reaction mixture does not contain a reaction inhibitor in the three-stage reaction and has a composition.
- the reaction mixture is characterized by containing a buffer component that moderates the reaction activity of the enzyme that catalyzes the addition reaction. This is to prevent excessive addition of a nucleotide having a specific base at the terminus of the nucleotide chain and facilitate the subsequent degradation reaction that degrades the sequence of the added nucleotide.
- a divalent metal cation other than cobalt ion can be used as an activity factor.
- a divalent metal cation other than cobalt ion can be used as an activity factor.
- the cobalt ion even when the modifying substance has the above-mentioned group, it is also capable of preventing precipitation.
- Manganese ions or magnesium ions can be preferably used.
- the enzyme catalyzing the addition reaction is terminal deoxynucleotidyl transferase
- 4- (2-hydroxyethyl) piperazine 1-ethane sulfonic acid, 2-morpholino ethane sulfone is used as a buffer component.
- An acid or 3,3-dimethyldaltaric acid can be preferably used.
- the specific base of the nucleotide to be added is not a base included in the original (natural) nucleotide chain, that is, adenine, guanine, cytosine and thymine, and these bases are alkylated. It may be a mutated base which has been deaminated, halogenated, hydroxylated or acidified. In the case of a nucleotide having such a specific base, the nucleotide chain itself to be modified itself can maintain the initial state when a specific degrading enzyme acts on it.
- a DNA glycosylase or a DNA repair enzyme can be used as a degrading enzyme.
- a DNA glycosylase or a DNA repair enzyme can be used as a result, in the sequence of the added nucleotide, elimination of the base, ring opening of the doxyribose and dissociation of the tertiary phosphate group occur, and an aldehyde group is formed at the ⁇ terminal of the nucleotide chain.
- the nucleotide to be added is 2'-deoxyuridine ⁇ monophosphate.
- uracil DNA glycosylase can be preferably used as a degrading enzyme.
- the modifying substance may be a substance having -NH.
- NH present in the modifier is
- the modifying substance is a substance that labels and labels the nucleotide chain.
- a decorating substance may be a fluorescent substance, a vitamin, a lipid, an amino acid, an oligopeptide, a protein, or an exogenous substance! /.
- the modifying substance may be an intervening substance for binding the nucleotide chain to the substrate.
- the potent modifier may be a compound having an amino group and a thiol group. Further, it may be a compound having an amino group and an alkoxysilyl group that forms a silanol group by hydrolysis.
- the nucleotide chain having an arbitrary base sequence, the nucleotide having a specific base, and the end of the nucleotide chain are described above.
- An enzyme that catalyzes the addition reaction of nucleotides a degrading enzyme that acts on the nucleotide, such as a DNA glycosylase or a DNA repair enzyme, and a nucleotide added by the enzyme is decomposed by the decomposing enzyme, whereby the end of the nucleotide chain A modifying substance having a binding ability to the aldehyde group formed at the end can be mixed.
- uracil A modified product containing HN in the reaction mixture after mixing with DNA glycosylase and heat-treating or alkali-treating the reaction mixture is added.
- the nucleotide chain can be modified with a desired modified substance simply and in a short time while maintaining the original state, that is, without adding extra nucleotides. Can do. Also involved in the force of a single-stranded nucleotide chain Not.
- FIG.1 Schematic diagram showing the principle of the nucleotide chain modification method of the present invention.
- FIG. 2 Schematic diagram showing the process of labeling and labeling nucleotide chains using the reaction of Fig. 1.
- FIG. 3 Schematic diagram showing the process of immobilizing a nucleotide chain on a noble metal substrate using the reaction of Fig. 1.
- FIG. 4 A polyacrylamide gel electrophoresis diagram showing the reaction status in each reaction process of the nucleotide chain modification method of the present invention.
- FIG. 5 Polyacrylamide gel electrophoresis showing the effect of enzyme activity factor in the nucleotide chain modification method of the present invention.
- FIG. 6 Polyacrylamide gel electrophoresis showing the effects of enzyme activity factor and buffer component in tailing reaction in the nucleotide chain modification method of the present invention.
- FIG. X in the figure represents an arbitrary base of adenine, guanine, thymine, and cytosine, and U represents a uracil base.
- n represents an arbitrary natural number
- m represents 0 or an arbitrary natural number.
- dUTP 2'-deoxyuridine ⁇ triphosphate
- TdT terminal deoxynucleotidyl transferase
- UDG uracil-DNA glycosylase
- an activity factor that activates TdT it is desirable to use magnesium ions or manganese ions which are divalent cations.
- TdT's polymerase action causes the following expression at the 3 'end of the nucleotide chain (I):
- 2-Deoxyuridine 5 monophosphate (hereinafter abbreviated as “dUMP”) is tailored in a linear chain to produce a nucleotide chain (II).
- dUMP diphosphate
- the uracil base of tailed dUMP is dissociated by the action of UDG, and the glycosidic bond of deoxyribose is hydrolyzed to form a nucleotide chain (III) with an aldehyde group.
- the reaction mixture containing the generated nucleotide chain (III) is heated at 90 to: L00 ° C for 5 to 15 minutes, or sodium hydroxide solution or water is added to the reaction mixture.
- An alkali treatment is performed by dropping a strong alkali solution such as a potassium oxide solution. From this, the decomposed tailing moiety is dissociated to obtain a nucleotide chain (IV) in which an aldehyde group is directly formed at the end of the starting nucleotide chain (I).
- ⁇ in the middle represents a compound, molecule, or the remainder of the substance constituting the modifying substance). This makes it possible to form NH at the end of NH
- a Schiff base is formed between NH and the aldehyde group, and the 3 'end is directly modified with a modifying substance. Including the extra nucleotides decorated, a nucleotide chain (V) is obtained.
- Cobalt ions As an active factor of TdT described above, cobalt ions have been frequently used. Cobalt ions have NHs that modify nucleotide chains in this way.
- the magnesium ion and manganese ion which are preferably used as an active factor of TdT, do not form an insoluble precipitate with the modifying substance.
- Magnesium ions and manganese ions have lower enzyme activity than cobalt ions, but by using such ions, the amount of tailing of dUMP by TdT can be limited, so nucleotide chains It is possible to facilitate the progress of the reaction by UDG using dUMP tailored to the substrate, that is, to rapidly digest the substrate by UDG.
- dUMP can act as a substrate for uracil DNA glycosylase by tailing at least two or more of the nucleotide strands to be modified in a linear chain.
- the method for modifying a nucleotide chain of the present invention is not a method for incorporating a modifying substance using a replication reaction or a transcription reaction. It does not depend on the length.
- the modification time can be significantly reduced compared to the method of modifying the end by a cross-linking condensation reaction (for example, Nucleic Acids Res. 13-1529 1985).
- a cross-linking condensation reaction for example, Nucleic Acids Res. 13-1529 1985.
- nucleotide chain has a length of several tens of nucleotides that can be chemically synthesized
- a nucleotide chain having a specific base sequence is synthesized in advance, whereby the first stage reaction (nucleotide chain It is also possible to omit (I) ⁇ nucleotide chain (II).
- aminooxybiotin aminooxymethylcarbohydrazino-one D-piotin
- V nucleotide chain in which piotin is directly bonded to the 3 ′ end. it can.
- the nucleotide chain labeled with thiotin can be suitably used as a probe or target for gene analysis such as hybridization.
- a thiol having an amino group such as 8-amino- A modified nucleotide chain in which 8 amino-1 octanethiol (residue) is bonded directly to the ⁇ terminal of the nucleotide chain by causing condensation between the aldehyde group and the amino group by reacting with 1 octanethiol (B). Get (V).
- the nucleotide chain (V) having the thiol group is brought into contact with a noble metal substrate (C) such as gold by a dropping method to form a strong covalent bond between the thiol group and the noble metal.
- a noble metal substrate (C) such as gold
- the nucleotide chain (V) can be immobilized on the substrate (C).
- a metal substrate such as a precious metal or a glass with a metal thin film
- a metal thin film is used as a plastic support, it is bonded to a thiol group having a binding property to the metal substrate or the metal thin film and a nucleotide chain.
- 1-NH with both properties
- Aminoalkanethiols such as No 1 octanethiol can be used as modifiers.
- a silanol group having a bonding property to glass has a bonding property to an alkoxysilyl group such as a methoxysilyl group or an ethoxysilyl group generated by carohydrolysis and a nucleotide chain. 1 Gamma amino where both NHs exist
- Silane coupling compounds such as propyltriethoxysilane can be used as modifiers.
- tailing dUMP having a uracil base and decomposing it by acting UDG have been described.
- adenine, guanine, and cytosine contained in natural nucleotide chains.
- nucleotides with bases i.e., 2'-deoxyadenosine
- resulting from mutations such as alkylation, deamination, halogenation, hydroxylation or acidation of thymine.
- Monophosphate 2'-deoxycytidine 5'-monophosphate, 2'-deoxyguanosine ⁇ monophosphate and 2monodeoxythymidine ⁇ other than monophosphate, 2'-deoxyribonucleotide ⁇ (Monophosphoric acid) may be used.
- the above-mentioned uracil is obtained by deaminating the amino group present in the carbon at the 4-position of cytosine and mutating it to a carbo group.
- hypoxanthine is obtained by deaminating the amine present in the carbon at the 6th position of adenine and mutating it to a carboxylic group; 3-methyl is obtained by mutating the nitrogen at the 3rd position of adenine. It is adenine; the 8th carbon of guanine is acidified and the carbonyl group is mutated to 8-oxoguanine (the encoding of each base is from the International Pure and Applied Chemistry Union (IUPAC)). According to standards.
- IUPAC International Pure and Applied Chemistry Union
- nucleotide chain remains in the state of the initial nucleotide chain structure and configuration before the modification reaction.
- the guanine-noguanine mismatch modifier should have a binding group for the functional group formed on the nucleotide chain.
- the functional group is an aldehyde as described above, a group containing HN—, for example
- Mino group (H N—), hydrazino group (H NHN—), aminooxy group (H NO—), etc. are suitable.
- the modifying substances for labeling and labeling include fluorescein, Texas red, rhodamine, Cy3, which are fluorescent substances having an aminooxy group, A cyanine compound typified by Cy5 or non-fluorescent digigosigenin can be used. Modification of the nucleotide chain with a fluorescent substance is useful for gene analysis, especially Fluorescence in situ Hybridization (FISH method). Biotin is an example of vitamin and digigosigenin is an example of lipid.
- Amino acids, oligopeptides, and proteins can also be used because they have amino groups.
- amino acids phenylalanine, tryptophan, and tyrosine can be preferably used because they have fluorescence.
- Non-fluorescent amino acids, peptides, and the like can also be used by binding fluorescein or the like (hereinafter referred to as a labeled compound) to the side chain.
- a peptide has a side chain corresponding to the number of amino acids constituting the peptide, a plurality of labeled compounds can be bound.
- trilysine in which three lysines are linked has three amino groups in the side chain, so that a total of three labeling compounds having a carboxyl group, a succinimide group, etc. can be modified.
- proteins examples include alkaline phosphatase, peroxidase, colored and fluorescent phycoerythrin, transferrin, hemoglobin, green fluorescent protein, blue fluorescent protein, and equorin.
- peptides including proteins
- nucleotide chains using a substance obtained by modifying a hydrocarbon such as an amino-containing alkyl, aryl, cycloalkane, aromatic, saccharide or the like with a labeling compound. Can also be modified.
- exogenous substances such as gold colloids with amino groups formed on the surface, noble metal colloids such as silver colloids, magnetic fine particles, and fine particles typified by polymer fine particles such as polystyrene beads also modify nucleotide chains. It can be used as a substance.
- the modifying substance used for binding to the substrate may have a binding group for the functional group formed on the nucleotide chain and a binding group for the substrate, for example, an amino group and a thiol group.
- a binding group for the functional group formed on the nucleotide chain and a binding group for the substrate, for example, an amino group and a thiol group.
- an amino group and a thiol group As long as it has a compound, it can be used without any particular limitation.
- the above-mentioned aminoalkanethiol is a specific example.
- the hydrocarbon residue between the amino group and the thiol group may be in various forms such as straight chain, branched chain, cyclocyclic, aryl chain, aromatic ring, etc., its carbon number, position of amino group, etc. Can be changed.
- a gold substrate is generally used in a crystal oscillator microbalance method, a surface plasmon resonance method, or the like, but is not limited thereto, and in addition to gold, noble metals such as platinum and silver, copper, palladium, indium Nickel, iron, aluminum, and alloys thereof are also used.
- a silane coupling compound having an amino group may be used as a modifying substance, whereby glass, silicon, silica, alumina, My strength, and high molecular weight resin such as polystyrene, nylon, epoxy, etc. It is possible to fix the nucleotide chain to the substrate, and it can be applied to various conventional gene analysis techniques.
- silane coupling compound is a compound having an amino group and an alkoxysilyl group (for example, a methoxysilyl group, an ethoxysilyl group, etc.), the structure and the like are not particularly limited as in the case of alkanethiol. Is possible.
- silane coupling compounds that can be used include gamma-aminopropyltriethoxysilane, N-beta (aminoethyl) -1-gamma-aminopropylmethyldimethoxysilane, N-beta (aminoethyl) -1-gamma-aminopropyl. Trimethoxysilane, N beta (aminoethyl) 1 gamma 1 aminopropyltriethoxysilane, gamma aminopropyltrimethoxysilane and the like.
- Substances that originally do not have an amino group, an aminooxy group, or a hydrazine group can also modify the nucleotide chain through an appropriate spacer having these bonding groups.
- a substance having a carboxyl group can modify a nucleotide chain by interposing a substance having a diamino structure such as 1,2 diaminoethane or 1,6 diaminohexane as a spacer.
- a substance having a cyano group or a substance having halogenomagnesium such as a Grignard reagent can be used as the modifying substance.
- nucleotide chain to be modified a single-stranded chemically synthesized oligonucleotide having 25 nucleotides (commissioned to Sigma-Aldrich Japan) was used.
- This nucleotide chain The nucleotide sequence of 5TA is CTTATGATTTTTGTGTGAACCTCCC from the 5 ′ end, and DNA base sequence 5786-5810 of human skeletal muscle myosin heavy chain 1 (National Biotechnology Information Center, GenBank, Internet website (http: //www.n cbi.nlm.nih.gov/Genbank/index.html), accession number: NM — 005963 (as of February 2004)).
- A, G, T, and C represent zanin, guanine, thymine, and cytosine, respectively.
- aminooxybiotin (Dojindo Laboratories) was added to 2 mM, and the reaction mixture was diluted so that the nucleotide chain to be modified was 2 M, and then at 37 ° C for 1 hour. Reacted. Magnesium chloride is added because a divalent metal cation is required as an active factor of TdT.
- Lane 1 is a molecular weight marker (Promega)
- Lane 2 is an untreated nucleotide chain
- Lane 3 is a nucleotide chain after 2 hours of reaction at 37 ° C
- Lane 4 is 100 ° C for 15 minutes.
- Lane 5 shows the electrophoresis pattern of the nucleotide chain after modification with piotin.
- the molecular weight marker in lane 1 contains a nucleotide chain of 10 nt to 100 nt (every 10 nt interval, 10 nt indicates 10 nucleotides), and the arrows in the figure are 100 nt, 80 nt, 50 nt, 30 nt, 20 nt And lOnt electrophoretic migration positions are shown.
- the untreated nucleotide chain shown in lane 2 is 25 nt.
- the nucleotide chain is about 27-30 nt.
- TdT and UDG Coexistence in the reaction mixture shows that the dUMP tailing reaction to the nucleotide chain and the tailing dUMP decomposition reaction proceeded sequentially.
- nucleotide sequence configuration, chain length, type of modifying substance, reaction conditions, reaction composition (buffer solution, etc.) shown in Example 1 above are merely examples of the present invention. Any modification can be made without limitation.
- Lane 1 is the same molecular weight marker as in Example 1, and the arrows attached to the side of Lane 1 indicate the electrophoretic migration positions of 100 nt, 50 nt, 30 nt, 20 nt, and 10 nt, respectively.
- Lane 2 shows an untreated nucleotide chain
- lane 3 shows a modified nucleotide chain.
- No difference in electrophoretic mobility is observed between the nucleotide chains shown in lane 2 and lane 3.
- the nucleotide chain in lane 3 was not modified with piotin,
- reaction mixture composition is not replaced by the recovery of the nucleotide chain by ethanol precipitation or gel filtration. Immediate modification with mixing of modifying substances It is possible to migrate.
- a dUMP was tailed to the nucleotide chain in the same manner as in Example 1 except that various buffers (total amount: 50 ⁇ 1) containing the following active factor were used.
- Buffer 1 50 mM 4- (2 hydroxyethyl) piperazine 1-ethanesulfonic acid monobasic potassium chloride buffer (pH 7.2) containing 2 mM magnesium chloride (hereinafter referred to as magnesium) Containing sulfonate buffer solution)
- Buffer 2 50 mM 4- (2 Hydroxyethyl) piperazine 1-ethanesulfonic acid monohydrate-potassium potassium phosphate buffer (PH7.2) containing 2 mM manganese chloride (hereinafter referred to as manganese-containing sulfonic acid buffer) Called)
- Buffer 3 0.1M potassium potassium codylate buffer (pH 7.2) containing 2mM cobalt chloride (hereinafter referred to as cobalt-containing potassium codylate buffer)
- Lane 1 is the same molecular weight marker as in Example 1, and the arrows attached to the side of Lane 1 indicate the electrophoretic migration positions of 100 nt, 50 nt, 30 nt, 20 nt and lOnt, respectively. Lane 2 shows the untreated nucleotide chain.
- Lanes 3 to 6 show the time course of the nucleotide chain (30 minutes, 60 minutes, 90 minutes, 120 minutes) when using a magnesium-containing sulfonate buffer
- Lanes 7 to 10 show the time course of nucleotide chains (30 minutes, 60 minutes, 90 minutes, 120 minutes) when using manganese-containing sulfonate buffer
- Lanes 11 to 14 show the time course of the nucleotide chain (30 minutes, 60 minutes, 90 minutes, and 120 minutes) when using a cobalt-containing codylate buffer, respectively.
- the tailing reaction efficiency of dUMP is the highest when manganese-containing sulfonate buffer is used when cobalt-containing codylate buffer is used, followed by magnesium-containing sulfonate buffer. The lowest is when liquid is used.
- the combination of cobalt ion and codylate buffer has the highest reaction activity for TdT reaction. (For example, Bollum FJ, The Enzymes 10 ⁇ 145 1974 Academic Press) and the results are in agreement.
- the lower reaction efficiency of TdT is rather the decomposition reaction in UDG that is a subsequent reaction. This is desirable because the base mass for is reduced. This is to prevent excessive addition of nucleotides such as dUMP and facilitate the subsequent reaction to decompose the added nucleotides.
- the combination of cobalt ion and a strong codylic acid buffer solution is used from the viewpoint of the reaction efficiency of TdT, and from the viewpoint that cobalt ions are a factor for precipitating the modifying substance. If it is an arsenic compound! /, It is desirable to avoid it from the viewpoint.
- TdT when used as an enzyme that catalyzes an addition reaction, it is desirable to use a divalent metal cation other than cobalt ion, such as manganese ion or magnesium ion, as its activity factor. This can prevent precipitation of the modifying substance. It is also desirable to use a buffer component that moderates the TdT reaction activity, such as 4- (2-hydroxychetyl) piperazine 1-ethanesulfonic acid. Good buffers such as 2-morpholinoethanesulfonic acid or 3,3-dimethyldaltaric acid may be used.
- a buffer component that moderates the TdT reaction activity such as 4- (2-hydroxychetyl) piperazine 1-ethanesulfonic acid.
- Good buffers such as 2-morpholinoethanesulfonic acid or 3,3-dimethyldaltaric acid may be used.
- buffering agents do not have an amino group in their chemical structure, and therefore, such as 2-amino-1,2-hydroxymethyl-1,1,3-propanediol (commonly known as Tris), which is widely used as a buffering agent. It becomes possible to avoid the inhibition of the modification reaction caused by the buffer having one NH.
- the nucleotide chain obtained by chemical synthesis or replication reaction contains natural nucleotides. Not present in leotide, nucleotides with the bases shown in Table 1 may be formed in the sequence. For example, if there are many guanine cytosines in the nucleotide sequence of the nucleotide chain during the replication reaction of the nucleotide chain, incorporation of guanine-containing nucleotides in the replication reaction causes a reduction in replication efficiency. Instead of this, a nucleotide having hypoxanthine is used (for example, Nucleic Acids Res. 21-4427 1993). Thus, the nucleotide chain obtained by the replication reaction contains hypoxanthine in the sequence.
- This nucleotide chain is also decomposed by the subsequent decomposition reaction.
- a nucleotide having a base other than hypoxanthine may be appropriately selected and a tailing reaction may be performed. Since the DNA glycosylase or DNA repair enzyme used in the subsequent degradation reaction has specificity for nucleotides having bases serving as substrates, it is possible to avoid degradation of the nucleotide chain to be modified. .
- the method for modifying a nucleotide chain according to the present invention allows the 3 ′ end of the nucleotide chain to be modified to be quantitatively measured with any modifying substance while maintaining the original state of the nucleotide chain regardless of the length of the nucleotide chain. Since it can be stably and simply modified in a short time, it is useful for gene analysis that requires labeling, labeling, or immobilization of nucleotide chains.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200780020081XA CN101460619B (zh) | 2006-06-06 | 2007-06-04 | 核苷酸链的修饰方法 |
US12/303,313 US8129115B2 (en) | 2006-06-06 | 2007-06-04 | Method of modifying nucleotide chain |
JP2008520567A JP4823310B2 (ja) | 2006-06-06 | 2007-06-04 | ヌクレオチド鎖修飾方法 |
EP07744668.0A EP2028272B1 (en) | 2006-06-06 | 2007-06-04 | Method of modifying nucleotide chain |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006156731 | 2006-06-06 | ||
JP2006-156731 | 2006-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007142202A1 true WO2007142202A1 (ja) | 2007-12-13 |
Family
ID=38801453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/061309 WO2007142202A1 (ja) | 2006-06-06 | 2007-06-04 | ヌクレオチド鎖修飾方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8129115B2 (ja) |
EP (1) | EP2028272B1 (ja) |
JP (1) | JP4823310B2 (ja) |
CN (1) | CN101460619B (ja) |
WO (1) | WO2007142202A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2853829C (en) | 2011-07-22 | 2023-09-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
CN108513575A (zh) | 2015-10-23 | 2018-09-07 | 哈佛大学的校长及成员们 | 核碱基编辑器及其用途 |
CN110214183A (zh) | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物 |
EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
AU2020242032A1 (en) | 2019-03-19 | 2021-10-07 | Massachusetts Institute Of Technology | Methods and compositions for editing nucleotide sequences |
DE112021002672T5 (de) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz |
CN112920247B (zh) * | 2021-01-22 | 2022-12-27 | 南京大学 | 一种利用糖苷酶和氧胺化合物修饰dna的方法 |
US20220381984A1 (en) * | 2021-05-31 | 2022-12-01 | Jinan University | Fiber optic sensing apparatus and system |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5993100A (ja) | 1983-10-31 | 1984-05-29 | Wakunaga Seiyaku Kk | オリゴヌクレオチド誘導体 |
JPS59148798A (ja) | 1983-02-14 | 1984-08-25 | Wakunaga Seiyaku Kk | ビオチンヌクレオチド誘導体 |
JPS60166695A (ja) | 1984-02-09 | 1985-08-29 | Wakunaga Seiyaku Kk | オリゴヌクレオチド誘導体およびその製造法 |
JPS61112093A (ja) | 1984-11-05 | 1986-05-30 | Wakunaga Seiyaku Kk | ヌクレオチド誘導体 |
JPS61115094A (ja) | 1984-11-08 | 1986-06-02 | ライフ テクノロジ−ズ インコ−ポレ−テツド | 核酸ラベリング用新規ビオチンヌクレオチド |
JPS6399093A (ja) | 1981-04-17 | 1988-04-30 | エール ユニバーシテイ | ヌクレオチドの製造と該ヌクレオチドの使用の方法 |
JPH05331185A (ja) | 1992-05-29 | 1993-12-14 | Nippon Millipore Kogyo Kk | 核酸rnaの3′末端標識 |
JP2625095B2 (ja) | 1982-06-23 | 1997-06-25 | エンゾ バイオケム,インコーポレーテッド | 修飾ヌクレオチド |
JP2000063154A (ja) | 1998-08-12 | 2000-02-29 | Mitsubishi Chemicals Corp | 核酸固定用ガラスプレート |
JP2001066304A (ja) | 1999-06-21 | 2001-03-16 | Nisshinbo Ind Inc | 核酸固定化基板 |
JP3272365B2 (ja) | 1994-06-17 | 2002-04-08 | ザ ボード オブ トランティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 生体試料から成るミクロ配列を作成するための方法および装置 |
JP2002538836A (ja) | 1999-03-12 | 2002-11-19 | アマシャム バイオサイエンス ユーケイ リミテッド | 遺伝子発現の変化の分析 |
JP2003161731A (ja) | 2001-11-27 | 2003-06-06 | Sumitomo Bakelite Co Ltd | マイクロチップ用プラスチック基板、その製造方法及びその使用方法 |
JP2003246794A (ja) | 2002-02-26 | 2003-09-02 | Matsushita Kotobuki Electronics Industries Ltd | ヌクレオチド鎖修飾方法 |
JP2003526078A (ja) | 1998-02-04 | 2003-09-02 | コーニング インコーポレイテッド | アレイ印刷用基板 |
JP2005013173A (ja) * | 2003-06-30 | 2005-01-20 | Matsushita Electric Ind Co Ltd | ヌクレオチド鎖修飾方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
JPS5862600A (ja) | 1981-10-09 | 1983-04-14 | 富士写真フイルム株式会社 | 帯電防止層を有するx線螢光増感紙 |
US5681940A (en) * | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
DE19812103A1 (de) * | 1998-03-19 | 1999-09-23 | Bernauer Annette | Verfahren zur Synthese von Nucleinsäuremolekülen |
JP2004101516A (ja) * | 2002-07-19 | 2004-04-02 | Canon Inc | プローブ担体およびその製造方法 |
DE602004019926D1 (de) * | 2003-06-30 | 2009-04-23 | Panasonic Corp | Verfahren zur modifizierung einer nukleotidkette |
CN1687100A (zh) * | 2005-04-05 | 2005-10-26 | 奥林格斯技术有限公司 | 修饰性核苷酸及其用途 |
US20070218478A1 (en) * | 2005-12-16 | 2007-09-20 | Affymetrix, Inc. | Methods for fragmentation and analysis of nucleic acid |
-
2007
- 2007-06-04 CN CN200780020081XA patent/CN101460619B/zh not_active Expired - Fee Related
- 2007-06-04 WO PCT/JP2007/061309 patent/WO2007142202A1/ja active Application Filing
- 2007-06-04 US US12/303,313 patent/US8129115B2/en not_active Expired - Fee Related
- 2007-06-04 JP JP2008520567A patent/JP4823310B2/ja not_active Expired - Fee Related
- 2007-06-04 EP EP07744668.0A patent/EP2028272B1/en not_active Ceased
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07107998A (ja) | 1981-04-17 | 1995-04-25 | Univ Yale | 修飾されたヌクレオチドおよびその調製法およびその使用 |
JPS6399093A (ja) | 1981-04-17 | 1988-04-30 | エール ユニバーシテイ | ヌクレオチドの製造と該ヌクレオチドの使用の方法 |
JP2625095B2 (ja) | 1982-06-23 | 1997-06-25 | エンゾ バイオケム,インコーポレーテッド | 修飾ヌクレオチド |
JPS59148798A (ja) | 1983-02-14 | 1984-08-25 | Wakunaga Seiyaku Kk | ビオチンヌクレオチド誘導体 |
JPS5993100A (ja) | 1983-10-31 | 1984-05-29 | Wakunaga Seiyaku Kk | オリゴヌクレオチド誘導体 |
JPS60166695A (ja) | 1984-02-09 | 1985-08-29 | Wakunaga Seiyaku Kk | オリゴヌクレオチド誘導体およびその製造法 |
JPS61112093A (ja) | 1984-11-05 | 1986-05-30 | Wakunaga Seiyaku Kk | ヌクレオチド誘導体 |
JPS61115094A (ja) | 1984-11-08 | 1986-06-02 | ライフ テクノロジ−ズ インコ−ポレ−テツド | 核酸ラベリング用新規ビオチンヌクレオチド |
JPH05331185A (ja) | 1992-05-29 | 1993-12-14 | Nippon Millipore Kogyo Kk | 核酸rnaの3′末端標識 |
JP3272365B2 (ja) | 1994-06-17 | 2002-04-08 | ザ ボード オブ トランティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 生体試料から成るミクロ配列を作成するための方法および装置 |
JP2003526078A (ja) | 1998-02-04 | 2003-09-02 | コーニング インコーポレイテッド | アレイ印刷用基板 |
JP2000063154A (ja) | 1998-08-12 | 2000-02-29 | Mitsubishi Chemicals Corp | 核酸固定用ガラスプレート |
JP2002538836A (ja) | 1999-03-12 | 2002-11-19 | アマシャム バイオサイエンス ユーケイ リミテッド | 遺伝子発現の変化の分析 |
JP2001066304A (ja) | 1999-06-21 | 2001-03-16 | Nisshinbo Ind Inc | 核酸固定化基板 |
JP2003161731A (ja) | 2001-11-27 | 2003-06-06 | Sumitomo Bakelite Co Ltd | マイクロチップ用プラスチック基板、その製造方法及びその使用方法 |
JP2003246794A (ja) | 2002-02-26 | 2003-09-02 | Matsushita Kotobuki Electronics Industries Ltd | ヌクレオチド鎖修飾方法 |
JP2005013173A (ja) * | 2003-06-30 | 2005-01-20 | Matsushita Electric Ind Co Ltd | ヌクレオチド鎖修飾方法 |
Non-Patent Citations (26)
Title |
---|
"Molecular Cloning", 1989, pages: 11.23 |
ALVES A.M. ET AL., TETRAHEDRON LETTERS, vol. 30, 1989, pages 3089 |
BAUGH L.R. ET AL., NUCLEIC ACIDS RES., vol. 29, 2001, pages E29 |
BOLLUM FJ.: "The Enzymes", vol. 10, 1974, ACADEMIC PRESS, pages: 145 |
BRONSTEIN I. ET AL., METHODS ENZYMOL., vol. 217, 1993, pages 398 |
CHIPPING FORECAST, NATURE GENET., vol. 21, January 1999 (1999-01-01) |
CHOLLET A. ET AL., NUCLEIC ACIDS RES., vol. 13, 1985, pages 1529 |
CHU B.C.F ET AL., NUCLEIC ACIDS RES., vol. 11, 1983, pages 6513 |
COCUZZA A.J., TETRAHEDRON LETTERS, vol. 30, 1989, pages 6287 |
DALE R.M.K ET AL., BIOCHEMISTRY, vol. 14, 1975, pages 2447 |
GUO Z. ET AL., NUCLEIC ACIDS RES., vol. 22, 1994, pages 5456 |
LANGER P.R. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 6633 |
LEARY J.J. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 4045 |
MURASUGI A. ET AL., DNA, vol. 3, 1984, pages 269 |
NUCLEIC ACIDS RES., vol. 13, 1985, pages 1529 |
NUCLEIC ACIDS RES., vol. 21, 1993, pages 4427 |
REID T. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 1388 |
RICHARDSON R.W. ET AL., NUCLEIC ACIDS RES., vol. 11, 1983 |
RILEY L.K. ET AL., DNA, vol. 5, 1986, pages 337 |
SCHENA M. ET AL., SCIENCE, vol. 270, 1995, pages 467 |
SCHMITZ G.G. ET AL., ANAL. BIOCHEM., vol. 192, 1991, pages 222 |
See also references of EP2028272A4 |
SHALON D. ET AL., GENOME RES., vol. 6, 1996, pages 639 |
TRAINOR G.L. ET AL., NUCLEIC ACIDS RES., vol. 16, 1988, pages 11846 |
VAN GELDER R.N. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 1663 |
YU H. ET AL., NUCLEIC ACIDS RES., vol. 22, 1994, pages 3226 |
Also Published As
Publication number | Publication date |
---|---|
EP2028272A1 (en) | 2009-02-25 |
CN101460619A (zh) | 2009-06-17 |
JPWO2007142202A1 (ja) | 2009-10-22 |
JP4823310B2 (ja) | 2011-11-24 |
US20100015670A1 (en) | 2010-01-21 |
EP2028272A4 (en) | 2010-09-22 |
EP2028272B1 (en) | 2014-01-08 |
US8129115B2 (en) | 2012-03-06 |
CN101460619B (zh) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007142202A1 (ja) | ヌクレオチド鎖修飾方法 | |
KR102085242B1 (ko) | 표적 핵산 검출을 위한 방법 및 조성물 | |
EP3129505B1 (en) | Methods for clonal replication and amplification of nucleic acid molecules for genomic and therapeutic applications | |
EP1288313A2 (en) | System and method for assaying nucleic acid molecules | |
JP2020521508A (ja) | 核酸合成におけるターミナルトランスフェラーゼ酵素の使用 | |
WO2020227953A1 (zh) | 一种基于自发光的单通道测序方法 | |
WO2003078623A1 (fr) | Molecule fonctionnelle et son procede de production | |
Zhao et al. | Fluorometric determination of the p53 cancer gene using strand displacement amplification on gold nanoparticles | |
WO2008109945A1 (en) | Analysis of ribonucleic acid | |
Athapattu et al. | Solid-phase XRN1 reactions for RNA cleavage: application in single-molecule sequencing | |
MX2008007626A (es) | Mitigacion de la distorsion de adn de cont-1 en hibridizacion de acido nucleo. | |
CN100355886C (zh) | 核苷酸链修饰方法 | |
CN117431300A (zh) | 一种检测方法和试剂盒 | |
US7223538B2 (en) | Post-synthesis labeling of nucleic acids, assays using nucleic acids that are labeled post-synthetically, single nucleotide polymorphism detection, and associated compounds and microarrays | |
JP5427408B2 (ja) | 目的の生体分子、特に核酸を含む生体試料を標識又は処理する方法 | |
US20230117083A1 (en) | Methods of nucleic acid synthesis | |
EP1647592B1 (en) | Method of modifying nucleotide chain | |
CA3223500A1 (en) | Methods and compositions for combinatorial indexing of bead-based nucleic acids | |
US8981070B2 (en) | Conjugate between a thiophilic solid phase and an oligonucleotide comprising a thiooxonucleotide | |
US20100291637A1 (en) | Method for modifying nucleotide chain | |
WO2003102179A1 (fr) | Nouveau procede de dosage d'acide nucleique au moyen d'un nucleotide marque | |
JP2003246794A (ja) | ヌクレオチド鎖修飾方法 | |
JP2006006179A (ja) | ヌクレオチド鎖修飾方法 | |
Zhang et al. | A solid-phase enzymatic synthesis platform for the facile production of 2′-fluoroarabinonucleic acid (FANA) and chimeric XNA oligonucleotides using an evolved XNA polymerase | |
JP5223267B2 (ja) | 遺伝子増幅産物の回収方法および遺伝子増幅産物の回収キット |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780020081.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07744668 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008520567 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12303313 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007744668 Country of ref document: EP |